TILT Biotherapeutics Reports Publication on its Oncolytic Immunotherapy Platform in Pancreatic Cancer
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, today announces that new preclinical data relating to the use of its oncolytic immunotherapy platform
Source: finanznachrichten.de